Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
AmbioPharm, Inc.
Pharmaceutical Preparation ManufacturingUnited States
Last verified 1 year agoambiopharm.com
AmbioPharm, Inc., a leading player in the pharmaceutical industry, is headquartered in the United States, with significant operational regions across North America and Asia. Founded in 2004, the company has established itself as a trusted provider of high-quality peptide manufacturing and development services. AmbioPharm's core offerings include custom peptide synthesis, contract manufacturing, and research services, distinguished by their commitment to quality and innovation.
With a focus on serving the biotechnology and pharmaceutical sectors, AmbioPharm has achieved notable milestones, including the expansion of its facilities to enhance production capabilities. The company is recognised for its competitive market position, driven by a dedication to customer satisfaction and a robust portfolio of unique products tailored to meet the evolving needs of its clients.
18
DitchCarbon score
-24 vs industry average
AmbioPharm, Inc.’s score of 18 is lower than 25% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at AmbioPharm, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for AmbioPharm, Inc. yet.
AmbioPharm, Inc.'s reported carbon emissions
AmbioPharm, Inc., headquartered in the US, currently does not report any carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established specific reduction targets or commitments under initiatives such as the Science Based Targets initiative (SBTi) or other climate pledges.
As a result, there is no information on their scope of emissions (Scope 1, 2, or 3) or any significant achievements in reducing carbon emissions. Without specific data or commitments, it is unclear how AmbioPharm is addressing climate change within its operations or supply chain.
In the absence of reported emissions or reduction initiatives, it is essential for AmbioPharm to consider developing a comprehensive climate strategy to align with industry standards and expectations for sustainability.
Assessing AmbioPharm, Inc. as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for AmbioPharm, Inc. and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
AmbioPharm, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for AmbioPharm, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
AmbioPharm, Inc.1 year ago
18
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more